Enzolytics Inc (ENZC)

[29YEARINVESTOR]

R&D Services Ltd. ("R&D"), under the leadership of Aneliya Vidinlieva, Manager Clinical Trials, assisted by Dr. Ivaylo Tsonev, Chief Medical Officer of Desing and three consultants assigned by the University of Pharmacology, will be performing the clinical trials. R&D and VIRO expect the clinical trials to begin in late 2023 or early 2024.

With locations across Bulgaria, where the Clinical Trials will be conducted, R&D services will manage all the administration of the Clinical Trials of ITV-1 conducted in public, municipal, and private healthcare institutions. R&D is certified to ISO 9001:2015, ISO 27001:2013, and ISO 14001:2015 quality assurance standards for services provided.
https://www.otcmarkets.com/stock/ENZC/news/Patient-Population-for-the-Clinical-Trials-of-ITV-1-has-been-Established-by-the-European-Medicines-Agency-EMA?id=413189